natgillin/translations-raw huggingface dataset:
Alternativ kan personer, som er påbegyndt Twinrix Voksen, gives en boosterdosis af en af de monovalente vacciner.
Alternatively, subjects primed with Twinrix Adult may be administered a booster dose of either of the monovalent vaccines.
Alternativ lysbeskyttelse kan bruges i renrummet,
Alternative light-protection may be used in the clean room.
alternative
alternate injection
Alternative analyseteknikker er ikke tilstrækkeligt følsomme.
Alternative assay techniques are not sufficiently sensitive.
Alternative behandlinger bør overvejes, især ved langtidsbehandling.
Consider alternatives particularly for long-term use.
Alternative doseringsregimer har været anvendt i kliniske studier.
Alternative dosing regimens have been used in clinical studies.
Alternative former for kontraception (ikke-hormonelle) bør overvejes (se pkt.
Alternative forms of contraception (non-hormonal) should be considered (see section 4.6).
Alternative former for kontraception skal anvendes.
Alternative forms of contraception should be used.
Alternative inhalerede eller nasale kortikosteroider kan overvejes.
Alternative inhaled or nasal corticosteroids may be considered.
alternative lægemidler til
alternative agents for
Alternative steder
Alternate sites are
Alternative steder er abdomen eller på ydersiden af overarmene.
Alternate sites are the abdomen or outer area of upper arms
Alternative svangerskabsfore- byggende metoder anbefales til kvinder i den frugtbare alder.
Alternative methods of contraception are recommended for women of childbearing potential.
Alternativer til
Integrase strand transfer inhibitor
Alternativer til
No dose adjustment
Alternativer til disse antibiotika bør
An alternative to these antibiotics, such as
Alternativer til erythromycin bør overvejes,
azithromycin, should be considered.
alternativer, skal
Tenofovir:
Alternativt blev der lokaliseret blå vitalfarvning i 66,96 % af de eksciderede lymfeknuder, der var detekteret med technetium Tc 99m-tilmanocept (omvendt konkor- dans).
Alternatively, vital blue dye localised in 66.96% of the excised lymph nodes detected by technetium Tc 99m tilmanocept (reverse concordance).
alternativt dosisregimen (se
orally twice daily, may be
Alternativt er det acceptabelt at rotere ved 1.000 rpm i ikke længere end 5 minutter.
Alternatively, swirling at 1000 rpm for no longer than 5 minutes is acceptable.
Alternativt kan aktivt kul også anvendes (de 11 dage behøver ikke være konsekutive, medmindre der er behov for at sænke plasma- teriflunomid hurtigt).
Alternatively, activated charcoal may also be used (the 11 days do not need to be consecutive unless there is a need to lower teriflunomide plasma concentration rapidly).
Alternativt kan CRIXIVAN administreres med et fedtfattigt, let måltid.
Alternatively, CRIXIVAN may be administered with a low–fat, light meal.
Alternativt kan Crixivan indtages med et let måltid med lavt fedtindhold.
Alternatively, Crixivan may be given with a low-fat, light meal.
Alternativt kan den orale opløsning anvendes.
Alternatively the oral suspension can be used.
Alternativt kan den vedlagte doseringssprøjte bruges til katte med en legemsvægt på mindst 2 kg.
Alternatively and for cats with a body weight of at least 2 kg, the measuring syringe provided in the package can be used.
Alternativt kan der foretages intrauterin insemination (IUI).
Alternatively, Intra-Uterine Insemination (IUI) may be performed.
Alternativt kan der, når Prevenar gives inden for et almindeligt immuniseringsprogram (når alle spædbørn i et område vaccineres omtrent
Alternatively, when Prevenar is given as part of a ‘universal infant immunisation programme’ (when all infants in an area are vaccinated
Alternativt kan din læge beslutte at give en MIRCERA-startdosis på
Alternatively, your doctor may decide to administer a starting dose of MIRCERA of 0.6 micrograms for every kilogram of your body weight.
Alternativt kan din læge beslutte, at denne medicin ikke er velegnet til dig. hvis du har en større risiko for at udvikle en nyrelidelse.
Alternatively, your doctor may decide that this medicine is not suitable for you. if you are at greater risk of developing kidney disorders or if you are receiving other medicines that can affect your kidney.
Alternativt kan en dosis på 1,25 mg/m2 administreres over 30 minutter på dag 1-5 hver 3. uge.
Alternatively, a 1.25 mg/m2 dose could be administered over 30 minutes on Days 1–5 every 3 weeks.
Alternativt kan følgende initialdoser administreras som en enkelt injektion subkutant hos patienter, som ikke er i dialyse: 0,75 μg/kg én gang hver anden uge eller 1,5 μg/kg én gang månedligt.
Alternatively, in patients not on dialysis, the following initial doses can also be administered subcutaneously as a single injection: 0.75 μg/kg once every two weeks or 1.5 μg/kg once monthly.
Alternativt kan Gardasil gives efter et program med 3 doser:
Alternatively, Gardasil can be administered according to a 3-dose schedule:
Alternativt kan genotypebestemmelse overvejes.
Alternatively, genotyping may also be considered;
Alternativt kan injektionen gives via slangen med fistelnålen efter dialysen, efterfulgt af 10 ml isotonisk saltvand for at rense slangen og sikre tilfredsstillende injektion af præparatet i blodbanen (se Dosering, ”Voksne hæmodialysepatienter”).
Alternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10 ml of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation (see Posology, “Adult haemodialysis patients”).
Alternativt kan injektioner administreres i låret, hvis administration i deltoideusregionen af en eller grund er udelukket.
Alternatively, the injections can be administered in the thigh if there is any reason precluding administration in the deltoid region.
Alternativt kan Kyprolis administreres i en intravenøs pose.
Optionally, Kyprolis can be administered in an intravenous bag.
Alternativt kan Retacrit administreres med en initialdosis på 450 IE/kg subkutant 1 gang ugentligt.
Alternatively, Retacrit can be administered at an initial dose of 450 IU/kg subcutaneously once weekly.
Alternativt kan Silgard gives efter et program med 3 doser:
Alternatively, Silgard can be administered according to a 3-dose schedule:
Alternativt kan skylningen foretages som infusion.
Alternatively the flushing may be performed by infusion.
Alternativt kan skylningen udføres som infusion.
Alternately, the flushing may be performed by infusion.
Alternativt kan Telmisartan Actavis også bruges sammen med vanddrivende medicin, såsom hydrochlortiazid, der har vist sig at øge den blodtryksnedsættende virkning af telmisartan.
Alternatively, Telmisartan Actavis may be used in combination with diuretics (‘water tablets’) such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with telmisartan.
Alternativt kan telmisartan anvendes i kombination med et diuretikum af thiazidgruppen, som har en additiv virkning på telmisartans blodtrykssænkende virkning.
Alternatively, telmisartan may be used in combination with thiazide-type diuretics, which have been shown to have an additive blood pressure lowering effect with telmisartan.
Alternativt kan Telmisartan Teva Pharma også bruges sammen med vanddrivende medicin, såsom hydrochlorthiazid, der har vist sig at øge den blodtryksnedsættende virkning af Telmisartan Teva Pharma.
Alternatively, Telmisartan Teva Pharma may be used in combination with diuretics (“water” tablets) which have been shown to have an additive blood pressure lowering effect with Telmisartan Teva Pharma.
Alternativt kan voluminet (ml)c af rekonstitueret Cancidas overføres til en reduceret mængde 0,9%, 0,45% eller 0,225% natriumchloridinfusionsvæske eller Ringer-lactatinfusionsvæske, men den endelige koncentration af infusionsvæsken må ikke overstige 0,5 mg/ml.
Alternatively, the volume (ml)c of reconstituted CANCIDAS can be added to a reduced volume of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride Injection or Lactated Ringers
Alternativt kan voluminet (ml)c af rekonstitueret CANCIDAS overføres til en reduceret mængde 0,9%, 0,45% eller 0,225% natriumchloridinfusionsvæske eller Ringer-lactatinfusionsvæske, men den endelige koncentration af infusionsvæsken må ikke overstige 0,5 mg/ml.
Alternatively, the volume (ml)c of reconstituted CANCIDAS can be added to a reduced volume of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride Injection or Lactated Ringers Injection, not to exceed a final concentration of 0.5 mg/ml.
Alternativt kan voluminet (ml)c af rekonstitueret Caspofungin Accord overføres en reduceret mængde 0,9%, 0,45% eller 0,225% natriumchlorid infusionsvæske eller Ringer-lactat- infusionsvæske, men den endelige koncentration af infusionsvæsken må ikke overstige0,5 mg/ml.
Caspofungin Accord can be added to a reduced volume of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride solution for infusion or Lactated Ringers solution for infusion, not to exceed a final concentration of 0.5 mg/mL.
Alternativt kan voluminet (ml)c af rekonstitueret Caspofungin Accord overføres til en reduceret mængde 0,9%, 0,45% eller 0,225% natriumchlorid infusionsvæske eller Ringer-lactat- infusionsvæske, men den endelige koncentration af infusionsvæsken må ikke overstige 0,5 mg/ml.
Alternatively, the volume (mL)c of reconstituted Caspofungin Accord can be added to a reduced volume of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride solution for infusion or Lactated Ringers solution for infusion, not to exceed a final
Alternativt skal behandlingen med CYP3A4-substrat afbrydes under behandling med Ketek.
Alternatively, interruption in the treatment with the CYP3A4 substrate should be made during treatment with Ketek.
alterstatninger, der indeholder kalium
alt substitutes containing potassium
alterstatninger, der indeholder kalium
alt substitutes containing potassium,
Altid at anbringe flerdosisnæsesprayen i den børnesikrede æske efter brug.
Always to put the multi-dose nasal spray back in the child-resistant box after use.
Altid at opbevare Instanyl utilgængelig og ude af syne for børn, da det kan være skadeligt for dem.
Always to keep Instanyl out of the reach and sight of children since it can be harmful to them.
Altid at sætte den børnesikrede hætte tilbage på flerdosisnæsesprayen DoseGuard og lukke den efter brug.
Always to put the child-resistant cap back on to the multi-dose nasal spray DoseGuard, and close after use.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) var et studie designet til at undersøge fordele ved at tilføje aliskiren til en standardbehandling med en ACE-hæmmer eller en angiotensin-II-receptorblokker hos patienter med type 2 diabetes mellitus og kronisk nyresygdom, kardiovaskulærsygdom eller begge.
ALTITUDE (Aliskiren Trial in Type 2 Diabettes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) var et studie, der skulle undersøge fordelen ved at tilføje aliskiren til standardbehandling med en ACE- hæmmer eller en angiotensin II-receptorantagonist hos patienter med type 2-diabetes mellitus og kronisk nyresygdom, kardiovaskulær sygdom eller begge.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) var et studie, der skulle undersøge fordelen ved at tilføje aliskiren til standardbehandling med en ACE- hæmmer eller en ARB hos patienter med type 2-diabetes mellitus og kronisk nyresygdom, kardiovaskulær sygdom eller begge.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an ARB in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) var et studie, der skulle undersøge fordelen ved at tilføje aliskiren til standardbehandling med en ACE- hæmmer eller en ARBer hos patienter med type 2-diabetes mellitus og kronisk nyresygdom, kardiovaskulær sygdom eller begge.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an ARB in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) var et studie, der skulle undersøge fordelen ved at tilføje aliskiren til standardbehandling med en ACE-hæmmer eller en angiotensin II-receptorantagonist hos patienter med type 2-diabetes mellitus og kronisk nyresygdom, kardiovaskulær sygdom eller begge.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
alu) Blister
blister (PVC/PE/PVDC/alu)
Alu-alu blister.
Alu/Alu blisters.
Alu-blisterpakninger af PA/Alu/PVC:
PA/Alu/PVC – Alu blisters:
Alu-blisterpakninger af PVC/polychlortrifluorethylen (PCTFE): Enkeltpakninger med 7, 14, 28, 30, 50, 56, 90 eller 98 tabletter.
PVC/polychlorotrifluoroethylene (PCTFE) – Alu blisters: Single-packs containing 7, 14, 28, 30, 50, 56, 90 or 98 tablets.
Alu-PVC/PVDC blister.
Alu-PVC/PVdC blisters.
Alu/Alu blistere (kalender-blistere eller perforerede enkeltdosisblistere).
Alu/Alu blisters (calendar blisters or perforated unit dose blisters).
Alu/alu-blister indeholdende en hård kapsel.
Alu/alu blister containing one hard capsule.
ALU/ALU-blister PVC/ALU-blister
ALU/ALU blister PVC/ALU blister
Alu/alu-blister.
Alu/alu blister.
Alu/alu-blister:
Alu/Alu blisters
Alu/alu-blister:
For Alu/Alu blisters
Alu/alu-blister: 2 år
Alu/Alu blisters 2 years.
ALU/ALU-blisterkort PVC/ALU-blisterkort
ALU/ALU blister PVC/ALU blister
alu/PVC/PE/PVDC eller alu/PVC/PVDC blister.
Alu/PVC/PE/PVDC or Alu/PVC/PVDC blister.
Aluminium (som hydroxid) ...........................................................................................................
Aluminium (as hydroxide) .............................................................................................................
Aluminium (som hydroxid) ...........................................................................................................
Aluminium (as hydroxide) ................................................................................................................
Aluminium + tørremiddel – aluminiumblisters.
Aluminium + Dessicant – Aluminium blisters.
Aluminium blister á 7 tabletter (120 mg)
Aluminium blister of 7 tablets (120 mg)
Aluminium blister á 7 tabletter (15 mg)
Aluminium blister of 7 tablets (15 mg)
Aluminium blister á 7 tabletter (60 mg)
Aluminium blister of 7 tablets (60 mg)
Aluminium blisterkort i kartoner a 28, 35, 56, 70 eller 98 smeltetabletter pr. karton.
Aluminium blister strips in cartons of 28, 35, 56, 70 or 98 orodispersible tablets per carton.
Aluminium blisterkort i kartoner a 28, 35, 56, 70 eller 98 tabletter pr. karton.
Cold-formed aluminium blister strips in cartons of 28, 35, 56, 70 or 98 tablets per carton.
Aluminium blisterpakning
Blister Aluminium
Aluminium blisterpakninger
Aluminium blisters
Aluminium – Aluminiumblistere: Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.
Aluminium – Aluminium blisters: This medicinal product does not require any special storage conditions.
Aluminium- eller
Aluminium or
Aluminium- eller magnesiumhydroxid Calciumcarbonat
Aluminium or Magnesium hydroxide Calcium carbonate
Aluminium- eller magnesiumhydroxid, calciumcarbonat
Aluminium or magnesium hydroxide; calcium carbonate
Aluminium-aluminiumblistere: pakningsstørrelser a 28 og 30 tabletter.
Aluminium-Aluminium blisters : pack sizes of 28 and 30 tablets
Aluminium-aluminiumblistere: pakningsstørrelser a 28 tabletter.
Aluminium-Aluminium blisters : pack size of 28 tablets
Aluminium-blisterstrips i æsker med 14 x 1, 28 x 1, 49 x 1 tabletter.
Aluminium perforated unit dose blisters in cartons of 14 x 1, 28 x 1, 49 x 1 tablets.
Aluminium-blisterstrips i æsker med 14 x 1, 28 x 1, 49 x 1, 56 x 1, 98 x 1 tabletter.
Aluminium perforated unit dose blisters in cartons of 14 x 1, 28 x 1, 49 x 1, 56 x 1, 98 x 1 tablets.
Aluminium/ aluminium blisterpakninger: pakninger med 14, 28, 30, 50, 90, og 98 tabletter.
Aluminium/aluminium blisters; packs of 14, 28, 30, 50, 90 or 98 tablets.
Aluminium/ PVC-/PE-/PVdC--Alu-blister.
PVC/PE/PVdC-Alu blisters.
Aluminium/ PVC/PE/PVDC blister
Aluminium/ PVC/PE/PVDC blisters
aluminium/al uminium- blister
Blister (Alu/Alu)
Aluminium/aluminium (PVC) blister
blister alu/alu (PVC)
Aluminium/aluminium blister
Alu/Alu blisters
Aluminium/aluminium blister
Blister-alu/alu
Aluminium/aluminium blister, pakninger med 10, 30, 50, 60, 100 og 200 filmovertrukne tabletter.
Aluminium/aluminium blisters, packs of 10, 30, 50, 60, 100 and 200 film-coated tablets.
Aluminium/aluminium blister.
Aluminium / Aluminium blister.
Aluminium/aluminium blisterkort i kartoner a 28, 35, 56 eller 70 tabletter pr. karton.
Aluminium/aluminium blisters in cartons of 28, 35, 56 and 70 tablets per carton.
Aluminium/aluminium blisterkort i kartoner á 28, 56 og 98 filmovertrukne tabletter pr. karton.
Aluminium/aluminium blister strips in cartons of 28 ,56 and 98 film-coated tablets per carton.
Aluminium/aluminium eller PVC/aluminium blisterkort i æsker med 20, 30, 60 eller 90 tabletter.
Aluminium / Aluminium or PVC/Aluminium blisters placed into cardboard boxes containing 20, 30, 60 or 90 tablets.
Aluminium/aluminium peel-push blistre indeholdende 14 dispergible tabletter.
Aluminium /Aluminium peel-push blisters containing 14 dispersible tablets.
Aluminium/aluminium perforerede enkeltdosisblisterkort (kalendermærket) indeholdende 7 tabletter.
Aluminium/aluminium perforated unit dose blisters (calendar marked) containing 7 tablets.
Aluminium/aluminium perforeret enkeltdosis blister
Aluminium/Aluminium perforated unit dose blisters.
Aluminium/aluminium- eller PVC/PVdC/aluminium-blistere i pakningsstørrelser med 30, 60 eller 120 filmovertrukne tabletter.
Aluminium/aluminium or PVC/PVdC/Aluminium blister in pack-sizes of 30, 60 or 120 film-coated tablets.
Aluminium/aluminium- eller PVC/PVdC/aluminium-blistere indeholdende 10 filmovertrukne tabletter pr. blister, i pakningsstørrelser med 30, 60 eller 120 filmovertrukne tabletter.
Aluminium/aluminium or PVC/PVdC/Aluminium blister containing 10 film-coated tablets per blister, in pack-sizes of 30, 60 or 120 film-coated tablets.
ALUMINIUM/ALUMINIUM-BLISTER
ALUMINIUM/ALUMINIUM BLISTERS
Aluminium/Aluminium-blister (PA/Al/PVC//Al)
Aluminium/Aluminium (PA/Al/PVC//Al) blister
Aluminium/Aluminium-blister (PA/Alu/PVC/Alu)
Aluminium/Aluminium (PA/Alu/PVC/Alu) blister
Aluminium/aluminium-blister indsat i hylster (14 og 28 filmovertrukne tabletter) og pakket i æsker med 14, 28, 84 (3 hylstre med 28) og 98 (7 hylstre med 14) filmovertrukne tabletter.
Aluminium-aluminium blisters inserted in wallets (14 and 28 film-coated tablets) and packed in cartons containing 14, 28, 84 (3 wallets of 28), and 98 (7 wallets of 14) film-coated tablets.
Aluminium/aluminium-blister.
Aluminium//Aluminium blister.
Aluminium/aluminium-blistere:
Aluminium/aluminium blisters
Aluminium/aluminium-blistere: EU/1/12/763/001 30 Filmovertrukne tabletter EU/1/12/763/002 60 Filmovertrukne tabletter EU/1/12/763/003 120 Filmovertrukne tabletter
Aluminium/aluminium blisters EU/1/12/763/001 30 film-coated tablets EU/1/12/763/002 60 film-coated tablets EU/1/12/763/003 120 Film-coated tablets
Aluminium/aluminium-blistere: EU/1/12/763/007 30 Filmovertrukne tabletter EU/1/12/763/008 60 Filmovertrukne tabletter EU/1/12/763/009 120 Filmovertrukne tabletter
Aluminium/aluminium blisters EU/1/12/763/007 30 film-coated tablets EU/1/12/763/008 60 film-coated tablets EU/1/12/763/009 120 film-coated tablets
Aluminium/aluminium-blistere: EU/1/12/763/013 30 Filmovertrukne tabletter EU/1/12/763/014 60 Filmovertrukne tabletter EU/1/12/763/015 120 Filmovertrukne tabletter
Aluminium/aluminium blisters EU/1/12/763/013 30 film-coated tablets EU/1/12/763/014 60 film-coated tablets EU/1/12/763/015 120 film-coated tablets
Aluminium/aluminium-blisterkort (PA/Al/PVC/Al) i æske indeholdende 28 tabletter.
Aluminium/aluminium blisters (PA/Al/PVC/Al) in a carton containing 28 tablets.
Aluminium/aluminium-blisterkort i kartoner a 28, 56 eller 70 tabletter pr. karton.
Aluminium/aluminium blisters in cartons of 28, 56, 70 tablets per carton.
Aluminium/aluminium-blisterpakninger, pakninger a 14, 28, 30, 50,56,84, 90 og 98 tabletter.
Aluminium/aluminium blisters, packs of 14, 28, 30, 50, 56, 84, 90 and 98 tablets.
Aluminium/aluminium-blisterpakninger: pakninger med 14, 28, 30, 50, 56, 60, 90, 98, 112, 180, 196 (2 x 98) tabletter eller 60 x 1 tabletter i aluminium/aluminium perforeret enkeltdosis-blister.
Aluminium/aluminium blisters; packs of 14, 28, 30, 50, 56, 60, 90, 98 and 180 tablets.
Aluminium/Aluminiumblister
Aluminium/Aluminium Blister
Aluminium/Aluminiumblister: 40 tabletter.
Aluminium/Aluminium blister: 40 tablets.
Aluminium/aluminiumblisterkort i æsker med 2, 4 eller 12 tabletter.
Aluminium/aluminium blisters, in cartons containing 2, 4 or 12 tablets.
aluminium/magnesiumhydroxidantacida
hydroxide antacids nor famotidine
Aluminium/polyamid/aluminium/PVC-blister indeholdende 10 tabletter.
Aluminium/polyamide/aluminium/PVC blister containing 10 dispersible tablets.
Aluminium/PVC blisterkort i pakninger med 2, 4, 8, 10 og 12 film-overtrukne tabletter.
Aluminium/PVC blisters in cartons of 2, 4, 8, 10 and 12 film-coated tablets.
Aluminium/PVC blisterkort i pakninger med 4 film-overtrukne tabletter.
Aluminium/PVC blisters in cartons of 4 film-coated tablets.
Aluminium/PVC blisterkort pakket i karton (kalender).
Aluminium/PVC blister packed in cardboard boxes (calendar).
Aluminium/PVC-blisterkort i æsker, som indeholder 10, 20, 30, 50, 60, 100, 120 filmovertrukne tabletter og multipakninger indeholdende 200 (2 pakninger a 100) filmovertrukne tabletter.
Aluminium/PVC blisters placed into cardboard boxes containing 10, 20, 30, 50, 60, 100, 120 film- coated tablets and multipacks containing 200 (2 packs of 100) film-coated tablets.
Aluminium/PVC/PVDC-blisterkort i æsker, som indeholder 28, 30, 42, 56, 98 og 100 filmovertrukne tabletter.
Aluminium-PVC/PVDC blisters placed into cardboard boxes containing 28, 30, 42, 56, 98 and 100 film- coated tablets.
Aluminiumblister med en 165 mg kapsel
Aluminium blister containing one 165 mg capsule
Aluminiumbrev
Aluminium sachet
Aluminiumbrev
sachet (alu)
Aluminiumfolie/polyesterlamineret pose indeholdende 500 g – oralt pulver
Aluminium foil/polyester laminated bag containing 500 g – oral powder
ALUMINIUMFOREDE PLASTPOSER
ALUMINIUM-LINED PLASTIC BAGS
Aluminiumforede plastposer á 1 kg.
Aluminium-lined plastic bags of 1 kg.
Aluminiumforgiftning
Aluminium intoxication
Aluminiumhydroxid (Al3+) 4 mg
Aluminium hydroxide (Al3+) 4 mg
Aluminiumhydroxid (som 100%) 16,7 mg
Aluminium hydroxide (as 100%) 16.7 mg
Aluminiumhydroxid .......................................................................................................................
Aluminium hydroxide ....................................................................................................................